R01CA260961
Project Grant
Overview
Grant Description
Systematic Light Exposure Effects on Circadian Rhythms Entrainment, Inflammation, Neutropenic Fever, and Symptom Burden Among Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation - Project Summary
Multiple myeloma (MM) patients undergoing autologous stem cell transplantation (ASCT) experience clinically significant negative sequelae affecting disease prognosis, survival, and quality of life. These sequelae include an increase in the production of pro-inflammatory cytokines, higher occurrences of neutropenic fever, and higher symptom burden (e.g., depression, pain), which are associated with circadian rhythm disruption (CRD). CRD involves a disruption in the naturally occurring 24-hour cycles of hormone secretion, temperature, and activity. CRD raises the production of pro-inflammatory cytokines, unfolding a cascade of negative effects that include higher symptom burden and the risk of developing neutropenic fever. CRD has been associated with poorer prognosis and survival.
Our recently completed R21 study showed that morning circadian-effective illumination of patients' hospital rooms resulted in significantly higher nocturnal melatonin levels, reduced depression, and production of inflammatory cytokines compared to the circadian-ineffective group (control). In the active group, an improvement in sleep and reduction in neutropenic fever was observed. Our R21 results also showed a strong negative relationship between melatonin levels and pro-inflammatory cytokines. Therefore, for the proposed multi-site randomized controlled trial (RCT), we hypothesize that circadian entrainment resulting from morning light exposure will lead to better sleep, lower levels of pro-inflammatory cytokines and symptom burden, as well as fewer occurrences of neutropenic fever. We will investigate if circadian-effective illumination of patients' hospital rooms/outpatient settings during ASCT promotes circadian entrainment and improves sleep, and if circadian entrainment reduces inflammation. We will also investigate whether better entrainment and lower levels of pro-inflammatory markers are associated with fewer occurrences of neutropenic fever and reduced symptom burden.
The circadian stimulating light will be installed in the outpatient setting/hospital rooms since transplants are performed in both settings. A unique advantage of our intervention is that it does not require any patient effort because the circadian-active light is delivered throughout the entire room. The project will determine if:
1) Circadian-effective light compared to circadian-ineffective light, delivered during ASCT, results in circadian rhythm entrainment;
2) Circadian entrainment reduces pro-inflammatory cytokines and mediates the effects of circadian-effective light on the cytokines; and
3) Reduced levels of inflammatory cytokines are associated with a reduced occurrence of neutropenic fever and lower symptom burden in patients.
Multiple myeloma (MM) patients undergoing autologous stem cell transplantation (ASCT) experience clinically significant negative sequelae affecting disease prognosis, survival, and quality of life. These sequelae include an increase in the production of pro-inflammatory cytokines, higher occurrences of neutropenic fever, and higher symptom burden (e.g., depression, pain), which are associated with circadian rhythm disruption (CRD). CRD involves a disruption in the naturally occurring 24-hour cycles of hormone secretion, temperature, and activity. CRD raises the production of pro-inflammatory cytokines, unfolding a cascade of negative effects that include higher symptom burden and the risk of developing neutropenic fever. CRD has been associated with poorer prognosis and survival.
Our recently completed R21 study showed that morning circadian-effective illumination of patients' hospital rooms resulted in significantly higher nocturnal melatonin levels, reduced depression, and production of inflammatory cytokines compared to the circadian-ineffective group (control). In the active group, an improvement in sleep and reduction in neutropenic fever was observed. Our R21 results also showed a strong negative relationship between melatonin levels and pro-inflammatory cytokines. Therefore, for the proposed multi-site randomized controlled trial (RCT), we hypothesize that circadian entrainment resulting from morning light exposure will lead to better sleep, lower levels of pro-inflammatory cytokines and symptom burden, as well as fewer occurrences of neutropenic fever. We will investigate if circadian-effective illumination of patients' hospital rooms/outpatient settings during ASCT promotes circadian entrainment and improves sleep, and if circadian entrainment reduces inflammation. We will also investigate whether better entrainment and lower levels of pro-inflammatory markers are associated with fewer occurrences of neutropenic fever and reduced symptom burden.
The circadian stimulating light will be installed in the outpatient setting/hospital rooms since transplants are performed in both settings. A unique advantage of our intervention is that it does not require any patient effort because the circadian-active light is delivered throughout the entire room. The project will determine if:
1) Circadian-effective light compared to circadian-ineffective light, delivered during ASCT, results in circadian rhythm entrainment;
2) Circadian entrainment reduces pro-inflammatory cytokines and mediates the effects of circadian-effective light on the cytokines; and
3) Reduced levels of inflammatory cytokines are associated with a reduced occurrence of neutropenic fever and lower symptom burden in patients.
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
New York,
New York
100296504
United States
Geographic Scope
Single Zip Code
Related Opportunity
Analysis Notes
Amendment Since initial award the total obligations have increased 382% from $728,085 to $3,510,216.
Icahn School Of Medicine At Mount Sinai was awarded
Circadian Light Effects on MM Patients Undergoing ASCT
Project Grant R01CA260961
worth $3,510,216
from National Cancer Institute in July 2022 with work to be completed primarily in New York New York United States.
The grant
has a duration of 5 years and
was awarded through assistance program 93.395 Cancer Treatment Research.
The Project Grant was awarded through grant opportunity Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required).
Status
(Ongoing)
Last Modified 6/22/26
Period of Performance
7/22/22
Start Date
6/30/27
End Date
Funding Split
$3.5M
Federal Obligation
$0.0
Non-Federal Obligation
$3.5M
Total Obligated
Activity Timeline
Transaction History
Modifications to R01CA260961
Additional Detail
Award ID FAIN
R01CA260961
SAI Number
R01CA260961-1160981616
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Private Institution Of Higher Education
Awarding Office
75NC00 NIH National Cancer Institute
Funding Office
75NC00 NIH National Cancer Institute
Awardee UEI
C8H9CNG1VBD9
Awardee CAGE
1QSQ9
Performance District
NY-13
Senators
Kirsten Gillibrand
Charles Schumer
Charles Schumer
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| National Cancer Institute, National Institutes of Health, Health and Human Services (075-0849) | Health research and training | Grants, subsidies, and contributions (41.0) | $1,419,786 | 100% |
Modified: 6/22/26